United Therapeutics vs Viatris

United Therapeutics (UTHR), health care, and Viatris (VTRS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

United Therapeutics is worth $24.9B on the stock market and Viatris $23.4B: United Therapeutics is valued at 6% more. United Therapeutics's operating margin in its latest fiscal year was 46.9% and Viatris's -18.6%. Over the past year United Therapeutics's share price has moved +23.4% and Viatris's +93.7%.

Key facts

United Therapeutics market value
$24.9B
Viatris market value
$23.4B
United Therapeutics P/E
22.0
United Therapeutics revenue
$3.2BFY to 2025-12-31
Viatris revenue
$14.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

United Therapeutics vs Viatris: every measure side by side
Measure United Therapeutics Viatris
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$24.9Bhigher$23.4Blower
Revenue$3.2Blower$14.3Bhigher
Earnings$1.3Bhigher-$3.5Blower
Employees1,400lower30,000higher
Total assets$7.9Blower$37.2Bhigher
Valuation
P/E22.0—
P/S7.8higher1.6lower
P/B3.9higher1.7lower
Dividend yield0.00%lower2.31%higher
Profitability
Operating margin46.9%higher-18.6%lower
Balance sheet
Net assets$7.1Blower$14.7Bhigher
Total liabilities$783.8Mlower$22.5Bhigher
Total debt—$14.4B
Cash on hand$1.6Bhigher$1.3Blower
Price change
Today-0.64%higher-1.40%lower
1 year+23.4%lower+93.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns UTHR · Who owns VTRS

Further comparisons

Learn

Questions and answers

Which is bigger, United Therapeutics or Viatris?

By market value, United Therapeutics is the larger: $24.9B against $23.4B for Viatris. By revenue in its latest fiscal year, Viatris is the larger: $14.3B against $3.2B for United Therapeutics.

Which has the higher operating margin?

United Therapeutics: 46.9%, against -18.6% for Viatris. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Viatris: 2.31%, against 0.00% for United Therapeutics. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both United Therapeutics and Viatris?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold United Therapeutics and 9 hold Viatris.

Cite this page

Funkfolio, “United Therapeutics vs Viatris”, data as of 18 November 2026. https://funkfolio.com/compare/uthr-vs-vtrs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.